

LISTING OF CLAIMS:

-

(b) a corticosteroid; and

wherein each component (a), (b), and (c) are is optionally in the form of solvates or hydrates a solvate or hydrate thereof.

- 2

4. **(Original)** The pharmaceutical composition according to claim 1, wherein:
X⁻ is selected from the group consisting of: chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, and p-toluenesulfonate.
5. **(Original)** The pharmaceutical composition according to claim 1, wherein:
X⁻ is selected from the group consisting of: chloride, bromide, methanesulfonate, and p-toluenesulfonate.
6. **(Original)** The pharmaceutical composition according to claim 1, wherein X⁻ is bromide.
7. **(Original)** The pharmaceutical composition according to claim 1, wherein the corticosteroid is selected from flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, GW215864, KSR592, ST-126, dexamethasone, and mixtures thereof.
8. **(Original)** The pharmaceutical composition according to claim 1, wherein the corticosteroid is selected from flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, dexamethasone, and mixtures thereof.
9. **(Original)** The pharmaceutical composition according to claim 1, wherein the betamimetic is selected from bambuterol, bitolterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, pirbuterol, procaterol, reproterol, salmeterol, sulfoneterol, terbutaline, tolubuterol, 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulfonyl}ethyl]amino}ethyl]-2(3H)-benzothiazolone, 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-{4-[3-(4-

methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butylamino} ethanol, 5-hydroxy-8-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-one, 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert-butylamino)ethanol, 1-(4-ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert-butylamino)ethanol, and mixtures thereof.

10. (Original) The pharmaceutical composition according to claim 1, wherein the betamimetic is selected from formoterol, salmeterol, 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulfonyl }ethyl]amino}ethyl]-2(3H)-benzothiazolone, 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butylamino} ethanol, and mixtures thereof.

11. (Original) The pharmaceutical composition according to one of claims 1 to 10, wherein the weight ratio of the anticholinergic in the form of its cation to the corticosteroid is in the range from 1:250 to 250:1.

12. (Original) The pharmaceutical composition according to one of claims 1 to 10, wherein the weight ratio of anticholinergic to the betamimetic is in the range from 1:300 to 30:1.

13. (Original) The pharmaceutical composition according to one of claims 1 to 10, wherein the total amount of the anticholinergic, the corticosteroid, and the betamimetic is 1 µg to 10000 µg.

14. (Original) The pharmaceutical composition according to claim 1, wherein the total amount of the anticholinergic, the corticosteroid, and the betamimetic is 10 µg to 2000 µg.

16. (Currently Amended) The pharmaceutical composition according to claim 15, wherein the pharmaceutical composition is an inhalable powder, ~~propellant-containing aerosol composition,~~ or a propellant-free inhalable solution or suspension.

18. (Original) The pharmaceutical composition according to one of claims 2 or 3, wherein the pharmaceutical composition is an inhalable powder and the physiologically acceptable excipient has a maximum average particle size of up to 250 μm.

20. (Original) A capsule containing inhalable powder according to claim 18.

1

wherein X^- is an anion with a single negative charge;

(b) a corticosteroid; and

(c) a betamimetic,

wherein each component (a), (b), and (c) are optionally in the form of the solvates or hydrates thereof.

22. – 27. (Canceled)